


MS049 dihydrochloride

Cat. No.:	HY-100360A
CAS No.:	2095432-59-8
Molecular Formula:	C ₁₅ H ₂₆ Cl ₂ N ₂ O
Molecular Weight:	321.29
Target:	Histone Methyltransferase
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	MS049 dihydrochloride is a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC ₅₀ s of 34 nM and 43 nM, respectively. MS049 dihydrochloride reduces levels of Med12me2a and H3R2me2a in HEK293 cells. MS049 dihydrochloride is not toxic and does not affect the growth of HEK293 cells ^[1] .																
In Vitro	<p>MS049 dihydrochloride (0.1-10 μM; 20 hours) reduces the H3R2me2a mark in HEK293 cells in a concentration dependent manner (IC₅₀=0.97±0.05 μM)^[1].</p> <p>MS049 dihydrochloride (0.1-100 μM; 72 hours) inhibits endogenous PRMT4 methyltransferase activity in a concentration dependent manner resulting in reduced levels of cellular asymmetric arginine dimethylation of Med12 (Med12-Rme2a, IC₅₀=1.4±0.1 μM) in HEK293 cells^[1].</p> <p>MS049 dihydrochloride is selective for PRMT4 and PRMT6 over a broad range of epigenetic modifiers, including other PRMTs, PKMTs, DNMTs, KDMs, and methyllysine/methylarginine reader proteins, and non-epigenetic targets^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HEK293 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.1, 1, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>20 hours</td> </tr> <tr> <td>Result:</td> <td>Reduced the H3R2me2a mark in HEK293 cells in a concentration dependent manner (IC₅₀=0.97±0.05 μM).</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HEK293 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.1, 1, 10, 100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Reduced levels of cellular asymmetric arginine dimethylation of Med12 (Med12-Rme2a, IC₅₀=1.4±0.1 μM) in HEK293 cells.</td> </tr> </table>	Cell Line:	HEK293 cells	Concentration:	0.1, 1, 10 μM	Incubation Time:	20 hours	Result:	Reduced the H3R2me2a mark in HEK293 cells in a concentration dependent manner (IC ₅₀ =0.97±0.05 μM).	Cell Line:	HEK293 cells	Concentration:	0.1, 1, 10, 100 μM	Incubation Time:	72 hours	Result:	Reduced levels of cellular asymmetric arginine dimethylation of Med12 (Med12-Rme2a, IC ₅₀ =1.4±0.1 μM) in HEK293 cells.
Cell Line:	HEK293 cells																
Concentration:	0.1, 1, 10 μM																
Incubation Time:	20 hours																
Result:	Reduced the H3R2me2a mark in HEK293 cells in a concentration dependent manner (IC ₅₀ =0.97±0.05 μM).																
Cell Line:	HEK293 cells																
Concentration:	0.1, 1, 10, 100 μM																
Incubation Time:	72 hours																
Result:	Reduced levels of cellular asymmetric arginine dimethylation of Med12 (Med12-Rme2a, IC ₅₀ =1.4±0.1 μM) in HEK293 cells.																

REFERENCES

[1]. Shen Y et al. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6. J Med Chem. 2016 Oct 13;59(19):9124-9139.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA